RXRX · Company research
7 upcoming catalysts · 0 phase 2+ trials on file
View Stock opens Yahoo Finance. Prices and performance charts are provided there.
REC-4881 FDA registrational-path update in FAP, expected in the second half of 2026 (no exact date yet). A company milestone for Recursion (REC-4881 (MEK1/2 inhibitor) for familial adenomatous polyposis): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Recursion expects to report results from its Phase 1 study of REC-1245 (RBM39 degrader) for biomarker-enriched solid tumors and lymphoma in the second half of 2026 (no exact date yet). Phase 1 is an early safety study in a small group of people.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
REC-7735 PI3Ka H1047R inhibitor Phase 1/2 start in solid tumors, expected in the second half of 2026 (no exact date yet). A company milestone for Recursion (REC-7735 for PI3Ka H1047R-mutant solid tumors): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Recursion presents data on REC-4881 (MEK1/2 inhibitor) for familial adenomatous polyposis at a medical meeting on Nov 2, 2026. New numbers at a conference can move the stock as much as a formal announcement.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Recursion expects to report results from its Phase 1 study of REC-617 (CDK7 inhibitor) for advanced solid tumors in the first half of 2027 (no exact date yet). Phase 1 is an early safety study in a small group of people.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Recursion expects to report results from its Phase 1 study of REC-3565 (MALT1 inhibitor) for B-cell malignancies in the first half of 2027 (no exact date yet). Phase 1 is an early safety study in a small group of people.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Recursion expects to report results from its Phase 1 study of REC-4539 (LSD1 inhibitor) for small cell lung cancer in the second half of 2027 (no exact date yet). Phase 1 is an early safety study in a small group of people.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Recursion reported results from its Phase 2 study of REC-4881 for familial adenomatous polyposis on May 6, 2026. The study met its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Explore reported politician transactions and public investor statements connected to RXRX.
View source-linked activity ↗No phase 2+ trials cached for this company.
No recent headlines on file.